Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Feb 18, 2025
Date Accepted: Sep 20, 2025

The final, peer-reviewed published version of this preprint can be found here:

Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review

Abeck F, Hansen-Abeck I, Kött J, Garrahy E, Schneider SW, von Büren J

Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review

JMIR Dermatol 2025;8:e72704

DOI: 10.2196/72704

PMID: 41418299

PMCID: 12716827

Direct-to-consumer teledermatology for male androgenetic alopecia: a narrative review

  • Finn Abeck; 
  • Inga Hansen-Abeck; 
  • Julian Kött; 
  • Edward Garrahy; 
  • Stefan W. Schneider; 
  • Johannes von Büren

ABSTRACT

This narrative review examines the advantages and disadvantages of direct-to-consumer teledermatology for the treatment of male androgenetic alopecia, finding that this treatment modality improves access to care, ensures high adherence rates, and enhances patient satisfaction, while raising concerns about increased drug costs.


 Citation

Please cite as:

Abeck F, Hansen-Abeck I, Kött J, Garrahy E, Schneider SW, von Büren J

Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review

JMIR Dermatol 2025;8:e72704

DOI: 10.2196/72704

PMID: 41418299

PMCID: 12716827

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.